Navigation Links
NeurogesX Announces Presentation of Positive Phase 3 Clinical Data,at the Second International Congress on Neuropathic Pain Meeting,(NeuPSIG)

SAN CARLOS, Calif., June 07, 2007 /PRNewswire-FirstCall/ -- NeurogesX, Inc. announced today the presentation of clinical data from a positive Phase 3 trial in postherpetic neuralgia (PHN). Misha-Miroslav Backonja, M.D., Professor of Neurology at University of Wisconsin in Madison and lead academic investigator in the NeurogesX trial, plans to present the results of the study in a June 8 poster session at the Second International Congress on Neuropathic Pain in Berlin, Germany. Dr. Backonja's poster presentation is based on an abstract titled, "Localized Treatment with NGX- 4010 Significantly Reduced Pain for up to 12 Weeks: Results of A Randomized, Double-Blind, 12-Week Controlled Study in Postherpetic Neuralgia Patients."

The study evaluated the effect of a single application of NGX-4010, the Company's novel dermal patch, on pain due to PHN. The primary endpoint in this Phase 3 trial was achieved, demonstrating a statistically significant reduction in pain over an 8-week period (NGX-4010, -29.6% vs. control, -19.9%; p = 0.001). The reduction of pain was sustained over 12 weeks (NGX-4010, -29.9% vs. control, -20.4%; p=0.0016).

"The results of this pivotal Phase 3 trial demonstrate NGX-4010 is effective both alone and in combination with other neuropathic pain medications for the treatment of PHN," said Dr. Backonja. "We believe that NGX-4010's unique profile has the potential to provide a meaningful therapeutic alternative to traditional therapies that need to be taken daily, most of which have systemic side effects."

According to the Centers for Disease Control, there are approximately 1.0 million cases of shingles in the United States each year, and approximate one in five shingles sufferers go on to develop PHN. People with PHN experience pain and increased sensitivity of the skin that can persist for many years.

NeurogesX plans to complete a confirmatory Phase 3 trial in PHN in t
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:7/29/2014)... N.J. , July 29, 2014 Regado ... company focused on the Phase 3 clinical development of ... controllable antithrombotic drug system, today announced that it will ... Tuesday, Aug. 12, 2014, at 8:30 a.m. EDT to ... highlights. Interested participants and investors may access ...
(Date:7/29/2014)... July 29, 2014  Landauer, Inc. (NYSE: ... radiation measurement and monitoring, outsourced medical physics services and ... for the fiscal third quarter 2014 after the market ... The Company will host a conference call for investors ... Time (10 a.m. Eastern Time). Investors may access the ...
(Date:7/29/2014)... -- New high priced hepatitis C drugs will increase ... $2.9 to $5.8 billion next year, according to a ... by the Pharmaceutical Care Management Association (PCMA). Milliman projects ... much as 8.6 percent in 2015 as a result ... The study finds that the majority of ...
Breaking Medicine Technology:Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2
... , SAN CLEMENTE, Calif., Nov. 17 Three ... ages of two through 12 are extremely, very, or ... according to a survey conducted by Opinion Research Corporation ... research of natural remedies including Sinupret® for Kids, a ...
... , DURHAM, N.C., Nov. 17 Oxygen Biotherapeutics, Inc. ... has begun shipping Dermacyte(TM) Oxygen Concentrate Gel to customers ... which are going out today, cover orders received through ... for our company - actually shipping a product to ...
Cached Medicine Technology:Survey Finds Mothers Take Children's Health Into Their Own Hands 2Survey Finds Mothers Take Children's Health Into Their Own Hands 3Survey Finds Mothers Take Children's Health Into Their Own Hands 4Oxygen Biotherapeutics, Inc. Begins Shipping Cosmetic Product to Customers 2
(Date:7/30/2014)... 2014 Regents Health Resources, a consulting ... brought health care industry veteran Daryl Demonbreun and former ... lead the company’s ambitious plans to grow into a ... been moving along at a steady pace for nearly ... a notch,” says Bob Maier, founder and chief executive ...
(Date:7/29/2014)... 30, 2014 Recently, iFitDress.com, a well-known wedding ... satin bridal gowns . Aside from this, it has ... up to 68 percent off. All of its old and ... The company’s sales representative says excitedly, “We are pleased to ... new range, there are a lot of amazing items. It ...
(Date:7/29/2014)... Dublin, Ireland (PRWEB) July 30, 2014 ... announced the successful completion of a Phase I trial ... Acid (DGLA). , This study was a randomized, placebo-controlled, ... to assess the safety, pharmacokinetics and effect of food ... confirmed the benign safety profile of DGLA following both ...
(Date:7/29/2014)... Johns Hopkins researchers say they have discovered a chemical ... reactions that, if confirmed in larger studies, could give ... person,s risk of attempting suicide. , The discovery, described ... suggests that changes in a gene involved in the ... a significant role in turning what might otherwise be ...
(Date:7/29/2014)... July 29, 2014 Daily Gossip reveals in ... this program claims that he cured his condition with the ... to share part of his experience. , He claimed ... and naturally in just 4 days. Since his method turned ... sufferers from all around the world. , The Nasal ...
Breaking Medicine News(10 mins):Health News:Sferrella and Demonbreun Join Regents Health Resources 2Health News:Cheap Satin Bridal Gowns Recently Provided By Well-known Supplier iFitDress.com 2Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2
... HealthDay Reporter , FRIDAY, May 13 (HealthDay News) -- ... to a veterinary clinic near her home in Austin, Texas, when ... like herself," recalled Wong. After running a blood and ... Diabetes is on the rise as America,s cats and dogs grow ...
... in the brains of patients with Alzheimer disease collude, resulting ... cells, according to new findings published online in Neurobiology ... pathological forms of two proteins, amyloid beta and tau, which ... patients plaques and tangles may work in tandem ...
... News) -- Being well-informed about their disease may lead to ... and other emotions about their condition, according to new research. ... were taking medication to manage the disease, and had symptoms ... and abdomen. The women,s coping styles affected their levels ...
... By Dennis Thompson HealthDay Reporter , FRIDAY, May ... the punch line of jokes, prompting chuckles about "mystery meat" ... days, with childhood obesity reaching epidemic proportions in the United ... their kids fit and healthy through proper nutrition. "Five ...
... It,s something we just accept: the fact that the older we ... can leave our ,cars in the same parking lot each morning, ... day, it,s a challenge eight hours later to ,recall whether we ... can ,be introduced to new colleagues at a meeting and will ...
... May 12 (HealthDay News) -- Representatives for veteran TV ... a facility for surgery to remove a meningioma -- ... on the meninges, the brain,s protective outer membrane. ... monitoring this for years, and a neurosurgeon, Mary decided ...
Cached Medicine News:Health News:Fat Cats, Dogs Developing Diabetes, Report Finds 2Health News:Fat Cats, Dogs Developing Diabetes, Report Finds 3Health News:2 defective proteins conspire to impair the nerve cell's 'powerhouse' in Alzheimer's disease 2Health News:2 defective proteins conspire to impair the nerve cell's 'powerhouse' in Alzheimer's disease 3Health News:For Some Women, Knowing About Heart Failure Spurs Worry 2Health News:U.S. Pushes School Cafeterias Toward Healthier Offerings 2Health News:U.S. Pushes School Cafeterias Toward Healthier Offerings 3Health News:As time goes by, it gets tougher to 'just remember this' 2Health News:As time goes by, it gets tougher to 'just remember this' 3Health News:Brain Surgery for Mary Tyler Moore to Remove Benign Tumor 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: